10-Q/A: HCW Biologics Restates EPS, Reports Strong Revenue Growth

HCW Biologics Inc. has amended its Q1 2026 report to correct an earnings per share calculation error, while simultaneously reporting a significant increase in revenue driven by licensing agreements.

Summary

• HCW Biologics Inc. filed an amendment to its Q1 2026 Form 10-Q to correct a misapplication of the two-class method for calculating earnings per share (EPS), impacting basic and diluted EPS for the period.
• The restatement resulted in a decrease of approximately $728,000 in net income attributable to common stockholders and a decrease of $0.14 per share for the three months ended March 31, 2026.
• The company reported revenues of $6.5 million for the three months ended March 31, 2026, a substantial increase from $5,065 in the prior year period, primarily due to the Trimmune license agreement.
• Operating expenses decreased by 15% to $1.3 million in Q1 2026 compared to $1.5 million in Q1 2025, driven by lower manufacturing and clinical trial costs.
• The company continues to face substantial doubt regarding its ability to continue as a going concern, dependent on future financings.
• A material weakness in internal controls related to the precise review of technical accounting guidance for complex warrant instruments and financing transactions persists.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a slightly negative sentiment due to the restatement of financial results and the continued material weakness in internal controls, despite positive revenue growth.

Positives

• Significant revenue growth, with revenues increasing from $5,065 in Q1 2025 to $6.5 million in Q1 2026, largely due to the Trimmune license agreement.
• Operating expenses decreased by 15% to $1.3 million in Q1 2026 compared to $1.5 million in Q1 2025.
• The Trimmune license agreement closed on March 16, 2026, providing $3.5 million in gross cash proceeds and a minority equity interest in Trimmune.
• The company's clinical-stage compound HCW9302 dosed its first patient in a Phase 1 trial for alopecia areata, a significant milestone.
• Preclinical data for HCW11-018b showed promising results in shrinking tumors and preventing metastasis in animal models.

Negatives

• The company restated its Q1 2026 EPS due to the misapplication of the two-class method for calculating earnings per share, leading to a $0.14 per share decrease.
• A material weakness in internal controls over financial reporting persists, specifically concerning the precise review of technical accounting for complex warrant instruments and financing transactions.
• Substantial doubt exists regarding the company's ability to continue as a going concern, contingent on obtaining future debt or equity financing.
• The company's cash and cash equivalents decreased from $1.95 million at December 31, 2025, to $1.23 million at March 31, 2026.
• The company is facing potential delisting from Nasdaq due to non-compliance with the minimum bid price requirement.

Risks

• The company's ability to continue as a going concern is dependent on its ability to obtain debt or equity financings.
• A material weakness in internal control over financial reporting persists, specifically related to the precise review of technical accounting for complex warrant instruments and financing transactions.
• The company is subject to Nasdaq listing rules and is seeking stockholder approval to maintain compliance, particularly regarding warrant exercise prices and potential share issuances.
• The company faces ongoing risks related to inflationary cost environments, geopolitical risks, and other macroeconomic factors impacting supply chains, costs, and timelines.
• The company is involved in ongoing legal proceedings, including construction lien foreclosures and settlement negotiations, which could result in significant financial liabilities.
• The company's clinical development programs are subject to numerous risks, including delays in trials, regulatory hurdles, and the inherent uncertainty of drug development.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances its molecules through development and clinical trials. Its ability to continue as a going concern is dependent on obtaining future debt or equity financings. The company is also focused on advancing its clinical development programs, including HCW9302, HCW11-018b, and HCW11-040, and seeking corporate partners for commercialization.

Management Comments

• Management concluded that previously issued financial statements should no longer be relied upon due to the misapplication of the two-class method of calculating EPS.
• Management determined that certain common warrants contain contractual provisions that provide holders with nonforfeitable rights to participate in distributions, qualifying them as participating securities.
• Management concluded that the previously identified material weakness in internal control over financial reporting had not been remediated, relating to the precision of review controls over technical accounting for complex warrant instruments and financing transactions.
• Management believes its products have the potential to fundamentally change the treatment of autoimmune disorders, cancer, and other inflammatory diseases.

Industry Context

StockSavvy.ai notes that HCW Biologics operates in the highly competitive and capital-intensive biopharmaceutical sector. The company's focus on fusion immunotherapeutics for chronic inflammation-related diseases aligns with broader industry trends in oncology and autoimmune disease research. The significant revenue generated from the Trimmune license is a positive development, but the company's reliance on future financing and ongoing internal control issues are common challenges for clinical-stage biotechs.

Comparison to Industry Standards

• The revenue recognition from the Trimmune license ($6.5 million) is a significant achievement for a clinical-stage company, reflecting successful out-licensing of intellectual property, a common strategy in the biopharma industry.
• The company's R&D expenses as a percentage of revenue are high, typical for the industry, but the decrease in absolute terms for Q1 2026 compared to Q1 2025 warrants monitoring.
• The ongoing need for equity financings and the resulting dilution are standard for companies in this stage of development, though the company's efforts to regain Nasdaq compliance are critical.
• The restatement of EPS due to warrant classification is a procedural issue that, while corrected, highlights the complexity of financial reporting for novel financial instruments in the sector.

Corporate Governance

Legal Proceedings

• Ongoing litigation related to construction liens filed by subcontractors, with a settlement agreement with B&I Contractors, Inc. for $860,000.
• Negotiations with Cogent Bank regarding a forbearance agreement to cure mechanics liens.
• Settlement agreement with EirGenix, Inc. for manufacturing costs, with extended payment terms.
• The company is involved in various legal proceedings arising from normal business operations, with no assurance on outcomes.

Related Party Transactions

• The company's Founder and CEO, Dr. Hing C. Wong, invested $2.4 million in Senior Secured Notes.
• Other officers and directors, including Rebecca Byam, Scott T. Garrett, Gary M. Winer, and Rick S. Greene, also invested in Senior Secured Notes.
• Dr. Hing C. Wong and Scott T. Garrett invested in unsecured convertible promissory notes.
• A $1.5 million dividend was recorded as a noncash financing activity related to a transaction with an existing stockholder (deemed a related party).

Stakeholder Impact

• Shareholders: Potential dilution from future equity raises, impact of Nasdaq delisting risk, and the correction of EPS may affect investor perception.
• Creditors: The company's going concern status and reliance on financing impact debt holders.
• Employees: Continued operations and potential growth are dependent on successful financing and clinical development.
• Suppliers: Ongoing legal proceedings and settlement negotiations with entities like EirGenix could impact payment terms and relationships.

Next Steps

• The company will continue to advance its clinical development programs for HCW9302, HCW11-018b, and HCW11-040.
• Stockholder approval is required for warrant repricing and issuance, with proposals to be voted on at the Annual Meeting on June 15, 2026.
• The company will continue to seek corporate partners for commercialization of its reagent program.
• The company is working to regain compliance with Nasdaq listing rules, including the minimum bid price requirement.
• The company will continue to implement remediation plans for its material weaknesses in internal controls.

Key Dates

Recommendation

The company shows promising revenue growth and clinical development progress, but the restatement of EPS, persistent material weakness in internal controls, and the ongoing going concern doubt necessitate a cautious approach. The risk of Nasdaq delisting and the need for further financing are significant factors. A 'hold' recommendation reflects the balance between potential upside and substantial risks.

Keywords

HCW Biologics, Form 10-Q/A, Earnings Per Share, Restatement, Trimmune License, Clinical Trials, Biopharmaceutical, Internal Controls